Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG-5-00455
- Development stage
- Preclinical
- Lead developer
- Nobelpharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Cell Therapies, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
SG-5-00455 is an investigational **engineered bacterial cellular therapy** being developed by Second Genome for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The product uses an engineered *Lactococcus lactis* live biotherapeutic delivery system to provide oral, non-systemic delivery of the microbiome-derived protein SG-2-0776 directly in the gut. SG-2-0776 is designed to bind and inhibit plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2, with the intended effect of restoring epithelial barrier function, promoting mucosal healing, improving dysregulated tissue repair, and reducing fibrosis associated with intestinal inflammation. Preclinical colitis data described reductions in inflammatory pathology and improvement in fibrosis- and repair-associated gene expression, and the program was reported to be in IND-enabling development.
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)PAI-2 (Plasminogen activator inhibitor-2)
Beyond the preview
Go deeper on SG-5-00455.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SG-5-00455.